Hjem › Steatotisk leversykdom › North Carolina
Kliniske studier for Steatotisk leversykdom i North Carolina
13 studier for Steatotisk leversykdom søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- og 2 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- og 3 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- og 5 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
RekruttererObservasjonsstudie
Alder 18 til 42 · Kvinner · Oppdatert 13. apr. 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 3. apr. 2026 · NCT07495332Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.